The U.S. Treasury is set to review recent tax rules—and that means the crackdown that ended pharma’s tax-inversion-mania could be in for a change.

Teva contends that Mexican generics buy Rimsa sold defective, illegal products and lied about it. But a new memo from Mexico’s drug regulator doesn't help…

German drugmaker Stada has announced plans to sell itself for €5.32 billion ($5.63 billion) shortly after weighing a $3.7 billion private equity takeout.

After an M&A downturn in 2016, industry watchers have been hoping for a resurgence. But so far this year, deal activity has slowed even more.

Embattled Valeant has promised its investors $8 billion in asset sales—but as the company’s latest deal struggles continue to demonstrate, getting there may…

Novartis is denying a report out of India suggesting it may be looking to retreat from the increasingly competitive market for asthma and COPD drugs and is…

Sanofi is in talks to buy Flexion Therapeutics, a biotech with its lead product awaiting FDA approval, for more than $1 billion, according to a source close to…

Buyout target Stada is rolling out cost-cutting measures and new guidance in an attempt to bring in larger bids.

Allergan is facing potential fallout from shareholders who say Allergan’s share price has been stung by questionable generics pricing.

M&A